BioCardia Past Earnings Performance

Past criteria checks 0/6

BioCardia has been growing earnings at an average annual rate of 7.8%, while the Biotechs industry saw earnings growing at 10.1% annually. Revenues have been growing at an average rate of 9.8% per year.

Key information

7.8%

Earnings growth rate

41.4%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate9.8%
Return on equityn/a
Net Margin-1,999.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How BioCardia makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:6JU0 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-940
31 Mar 240-1040
31 Dec 230-1240
30 Sep 231-1340
30 Jun 230-1340
31 Mar 231-1240
31 Dec 221-1240
30 Sep 221-1250
30 Jun 222-1250
31 Mar 221-1350
31 Dec 211-1350
30 Sep 211-1250
30 Jun 210-1350
31 Mar 210-1350
31 Dec 200-1560
30 Sep 200-1660
30 Jun 200-1560
31 Mar 201-1660
31 Dec 191-1560
30 Sep 191-1560
30 Jun 190-1560
31 Mar 191-1460
31 Dec 181-1460
30 Sep 181-1460
30 Jun 181-1360
31 Mar 181-1360
31 Dec 170-1260
30 Sep 171-1260
30 Jun 171-1360
31 Mar 171-1250
31 Dec 161-1040
30 Sep 161-730
30 Jun 161-730
31 Mar 161-630
31 Dec 151-740
31 Mar 151-1050
31 Dec 141-1040
31 Dec 132-630

Quality Earnings: 6JU0 is currently unprofitable.

Growing Profit Margin: 6JU0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6JU0 is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.

Accelerating Growth: Unable to compare 6JU0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6JU0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.1%).


Return on Equity

High ROE: 6JU0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/27 14:46
End of Day Share Price 2024/05/30 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioCardia, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
Emanuela BranchettiH.C. Wainwright & Co.